Somatic mutations in TET2 occur in about 15% of patients with various myeloid cancers.

Objective. Because it has no unique clinical, biologic, or histologic features, reactive hemophagocytic syndrome may be difficult to distinguish from other diseases such as severe sepsis or hematologic malignancies. This study was undertaken to develop and validate a diagnostic score for reactive hemophagocytic syndrome.Methods. A multicenter retrospective cohort of 312 patients who were judged by experts to have reactive hemophagocytic syndrome (n ‫؍‬ 162), were judged by experts to not have reactive hemophagocytic syndrome (n ‫؍‬ 104), or in whom the diagnosis of reactive hemophagocytic syndrome was undetermined (n ‫؍‬ 46) was used to construct and validate the reactive hemophagocytic syndrome diagnostic score, called the HScore. Ten explanatory variables were evaluated for their association with the diagnosis of hemophagocytic syndrome, and logistic regression was used to calculate the weight of each criterion included in the score. Performance of the score was assessed using developmental and validation data sets.

No abstract

No abstract